FAST FACTS
FOUNDER(S):
William M. Pardridge, MD
INNOVATION(S):
Biotechnology/Pharmaceuticals
EMPLOYEES:
6
HEADQUARTERS:
Santa Monica, CA
FOUNDED:
2004
REVENUE:
$430,000 FY08
TSC MEMBER INSTITUTION(S):
University of California, Los Angeles
FUNDING AGENCY(S):
Department of Defense
National Institutes of Health
STATUS:
Private
|
ARMAGEN TECHNOLOGIES, INC.
BIOTECHNOLOGY FOR THE BRAIN
ABOUT THE COMPANY:
In the 1980s, Dr. William Pardridge, Professor of Medicine and Endocrinology at the University of California, Los Angeles (UCLA), and his research team were the first to show that there were receptor systems along the human blood-brain barrier (BBB) that acted as transport systems. In the two decades since, they have continued their research and, with the help of funding from the National Institutes of Health and the Department of Defense, have developed what they call “molecular Trojan horses” that can effectively deliver various drugs and gene therapies to the brain. ArmaGen Technologies, Inc. was founded in 2004 to use this technology to develop therapeutic products for treatment of conditions including Alzheimer’s disease, Parkinson’s disease, stroke, and brain cancer.
UNIVERSITY-BASED RESEARCH CONNECTION:
ArmaGen Technologies, Inc. was founded in 2004 by Dr. William Pardridge, Professor of Medicine and Endocrinology at UCLA. The company is a spin-off from Dr. Pardridge’s laboratory at UCLA. When it was founded in 2004, ArmaGen signed a patent agreement with the University of California that gave the company exclusive license rights to pending and world-wide issued patents comprising a broad patent estate covering multiple technology platforms for the delivery to the brain, and other organs, of drugs, recombinant proteins, and non-viral gene medicines.
ROLE OF FEDERAL RESEARCH FUNDING:
Dr. Pardridge’s research at UCLA has been funded by the National Institutes of Health and the Department of Defense. ArmaGen has received recent awards from the National Institute of Neurological Disorders and Stroke (NINDS) at NIH (September 2008) and the US Army (June 2008).
 Read The Full Report Here
|
Printer-Friendly Version
ARMAGEN TECHNOLOGIES, INC.